Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308587481> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4308587481 endingPage "2123" @default.
- W4308587481 startingPage "2115" @default.
- W4308587481 abstract "Purpose: To investigate the mechanism of action of dapagliflozin on diabetic nephropathy. 
 Methods: A rat model of diabetic nephropathy was established by injection of fructose-streptozotocin. Blood glucose and urinary protein levels were measured, while histopathological changes in kidney tissues were determined by hematoxylin & eosin staining (H & E). Serum levels of creatinine (Cr), blood urea nitrogen (BUN), malondialdehyde (MDA), superoxide dismutase (SOD), reduced glutathione (GSH), and lactate dehydrogenase (LDH) were evaluated by enzyme-linked immunosorbent assay (ELISA). Cell apoptosis and autophagy were investigated by evaluating apoptotic and autophagic protein expression by western blot. 
 Results: Administration of fructose-streptozotocin increased the blood glucose level of the rats (p < 0.001) and induced pathological changes in the kidney tissues, including glomerulosclerosis, renal tubule dilation, and inflammatory cell infiltration of rats. However, long-term treatment with dapagliflozin attenuated the fructose-streptozotocin-induced increases in Cr, BUN, and urinary protein and reversed the fructose-streptozotocin-induced decrease in Bcl-2 expression and increases in Bax and cleaved PARP expression in diabetic rats. Dapagliflozin also reversed the increases in MDA and LDH and decreases in SOD and GSH in diabetic rats. The fructose-streptozotocin-induced increase in p62 expression and decreases in LC3 and Beclin 1 expression were reversed by dapagliflozin. It upregulated miR-30e-5p expression and downregulated phosphorylated AKT and mTOR expression in diabetic rats. MicroRNA-30e-5p targeted AKT and inhibition of miR-30e-5p attenuated the dapagliflozin-induced decrease in p-AKT and p-mTOR expression in diabetic rats. 
 Conclusion: In fructose-streptozotocin-induced diabetic rats, dapagliflozin ameliorates kidney injury, suppresses cell apoptosis and oxidative stress, and promotes cell autophagy through upregulation of miR-30e-5p and inactivation of the AKT/mTOR pathway. Therefore, dapagliflozin is a potent therapeutic agent for the management of diabetic neuropathy." @default.
- W4308587481 created "2022-11-12" @default.
- W4308587481 creator A5010781360 @default.
- W4308587481 creator A5023372230 @default.
- W4308587481 creator A5066479209 @default.
- W4308587481 creator A5071672663 @default.
- W4308587481 creator A5083951959 @default.
- W4308587481 date "2022-11-03" @default.
- W4308587481 modified "2023-09-30" @default.
- W4308587481 title "Dapagliflozin relieves renal injury in a diabetic nephropathy model by inducing autophagy through regulation of miR-30e-5p/AKT/mTOR pathway" @default.
- W4308587481 doi "https://doi.org/10.4314/tjpr.v21i10.11" @default.
- W4308587481 hasPublicationYear "2022" @default.
- W4308587481 type Work @default.
- W4308587481 citedByCount "0" @default.
- W4308587481 crossrefType "journal-article" @default.
- W4308587481 hasAuthorship W4308587481A5010781360 @default.
- W4308587481 hasAuthorship W4308587481A5023372230 @default.
- W4308587481 hasAuthorship W4308587481A5066479209 @default.
- W4308587481 hasAuthorship W4308587481A5071672663 @default.
- W4308587481 hasAuthorship W4308587481A5083951959 @default.
- W4308587481 hasBestOaLocation W43085874811 @default.
- W4308587481 hasConcept C126322002 @default.
- W4308587481 hasConcept C134018914 @default.
- W4308587481 hasConcept C185592680 @default.
- W4308587481 hasConcept C190283241 @default.
- W4308587481 hasConcept C2778176769 @default.
- W4308587481 hasConcept C2779280383 @default.
- W4308587481 hasConcept C2779922275 @default.
- W4308587481 hasConcept C2780091579 @default.
- W4308587481 hasConcept C55493867 @default.
- W4308587481 hasConcept C555293320 @default.
- W4308587481 hasConcept C71924100 @default.
- W4308587481 hasConcept C75217442 @default.
- W4308587481 hasConcept C86554907 @default.
- W4308587481 hasConceptScore W4308587481C126322002 @default.
- W4308587481 hasConceptScore W4308587481C134018914 @default.
- W4308587481 hasConceptScore W4308587481C185592680 @default.
- W4308587481 hasConceptScore W4308587481C190283241 @default.
- W4308587481 hasConceptScore W4308587481C2778176769 @default.
- W4308587481 hasConceptScore W4308587481C2779280383 @default.
- W4308587481 hasConceptScore W4308587481C2779922275 @default.
- W4308587481 hasConceptScore W4308587481C2780091579 @default.
- W4308587481 hasConceptScore W4308587481C55493867 @default.
- W4308587481 hasConceptScore W4308587481C555293320 @default.
- W4308587481 hasConceptScore W4308587481C71924100 @default.
- W4308587481 hasConceptScore W4308587481C75217442 @default.
- W4308587481 hasConceptScore W4308587481C86554907 @default.
- W4308587481 hasIssue "10" @default.
- W4308587481 hasLocation W43085874811 @default.
- W4308587481 hasOpenAccess W4308587481 @default.
- W4308587481 hasPrimaryLocation W43085874811 @default.
- W4308587481 hasRelatedWork W1995071802 @default.
- W4308587481 hasRelatedWork W2004012005 @default.
- W4308587481 hasRelatedWork W2011709829 @default.
- W4308587481 hasRelatedWork W2055342276 @default.
- W4308587481 hasRelatedWork W2092993950 @default.
- W4308587481 hasRelatedWork W2095626059 @default.
- W4308587481 hasRelatedWork W2140892006 @default.
- W4308587481 hasRelatedWork W2158125198 @default.
- W4308587481 hasRelatedWork W2491477912 @default.
- W4308587481 hasRelatedWork W4312832728 @default.
- W4308587481 hasVolume "21" @default.
- W4308587481 isParatext "false" @default.
- W4308587481 isRetracted "false" @default.
- W4308587481 workType "article" @default.